Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolmitriptan Nasal Spray for Acute Migraine in Children (6-11 Years)
NCT03275922Phase 3Completed
- Sponsor
- Impax Laboratories
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zolmitriptan in migraine (2 arms), sponsored by Impax Laboratories. Primary endpoint: Pain-free status at 2 hours post treatment. Started Nov 2017; status: completed.
02
Drugs
zolmitriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03275922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275922.